APTO•benzinga•
Canaccord Genuity Maintains Buy on Aptose Biosciences, Lowers Price Target to $6
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 16, 2024 by benzinga